Please login to the form below

Not currently logged in
Email:
Password:

GSK partners with new science hub the Francis Crick Institute

Will work with the biomedical facility on an 'open innovation' basis

GSK HQ 

GlaxoSmithKline has signed a deal with the UK's newest biomedical research facility The Francis Crick Institute to help the firm with its drug development. 

The two groups will work on an 'open innovation' collaboration exploring new avenues of medical research and drug discovery across a broad range of diseases.

This is the first collaboration to be established between the Crick Institute - which incorporates both the Medical Research Council's National Institute for Medical Research and Cancer Research UK's London Research Institute - and a pharmaceutical company.

Teams of scientists from each organisation will work side-by-side in integrated teams at the Crick's world-leading centre of biomedical research in central London and GSK's global R&D hub in Stevenage. 

In a statement, GSK said: “The close proximity of these two sites and the institutions' complementary areas of expertise will create a fertile ground for collaborative, innovative research - exposing scientists to new ways of thinking and building capability within each organisation.”

Both Crick and GSK said that their scientists will see a major benefit from the collaboration by introducing new ways of working and stimulating the development of novel approaches to problems. 

The two groups will contribute in-kind resources, including lab space and the scientific expertise of 20 staff to the collaboration. 

GSK will also provide important research tools to the collaboration, including access to its non-development compound library, key antibodies, reagents and technologies.

A number of projects within this collaboration exploring diseases including HIV, malaria and cancer are expected to start in 2015, according to the firm, which will build up to 10-15 projects by next year.

GSK's president of pharmaceuticals R&D, Patrick Vallance, said: “As a company with deep research roots in the UK, we're enormously proud of this country's vibrant biosciences community and the cutting-edge biomedical research that takes place here. 

“That's why we continue to invest a quarter of our R&D spend in the UK and have collaborations in place with some of the country's top research institutions, which rank among the best in the world.”

Article by
Ben Adams

15th July 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics